Opioid Overdose – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Opioid Overdose Market Outlook

Thelansis’s “Opioid Overdose Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Opioid Overdose treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Opioid Overdose Overview

The term "opioids" encompasses compounds derived from the poppy plant (Papaver somniferum), along with semisynthetic and synthetic counterparts sharing similar properties that can engage with opioid receptors in the brain. Opioids, such as morphine, codeine, and fentanyl, are commonly employed for pain management due to their analgesic and sedative effects. Medications like methadone and buprenorphine are used for the maintenance treatment of opioid dependence. Upon ingestion, opioids can induce euphoria, a primary motivator for their non-medical use. This category includes substances like heroin, tramadol, and others. Owing to their pharmacological impact, opioids can pose risks to respiratory function, and an opioid overdose can result in fatality. Three indicative signs of an opioid overdose include pinpoint pupils, unconsciousness, and breathing difficulties. An opioid overdose transpires when there is an excessive, unopposed stimulation of the opiate pathway, leading to diminished respiratory effort and potential death. The incidence of opioid overdose is on the rise. Opioids operate by acting as potent agonists to the mu receptor within the endogenous opioid system, triggering a complex cascade of signals that involve dopamine release, pain signal blockade, and the emergence of euphoria. Opioid receptors are distributed in the brain, spinal cord, and gut. During an overdose, an exaggerated impact on the brain's respiratory rate regulation can result in respiratory depression and, ultimately, death.

• In the United States, more than 20 million people have been exposed to opium, contributing to the escalating frequency of opioid-related issues.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: